Literature DB >> 1568584

The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.

P Cantor1, P E Mortensen, J Myhre, I Gjorup, H Worning, E Stahl, T T Survill.   

Abstract

To determine the physiological role of circulating cholecystokinin (CCK), the effect of the CCK receptor antagonist MK-329 on upper digestive processes was investigated in six normal volunteers after a mixed meal. In a double-blind, two-period, randomized crossover design, the subjects received either 10 mg MK-329 or placebo orally 3 hours 15 minutes before the meal, which contained 51CrCl3 as food marker. A five-lumen tube with the tip in the distal duodenum allowed continuous marker infusion (57Co-B12) and duodenal aspiration as well as recordings of antral and duodenal motility patterns via three pressure sensors. Postprandially, MK-329 caused a significant reduction of 30%-60% (P less than 0.05) in pancreatic trypsin output during the initial three 15-minute periods; thereafter, the output was virtually the same than after placebo. Thus, the integrated enzyme response was only reduced by 15% (NS) during the 3-hour period beginning 15 minutes after the meal. In contrast, gallbladder contraction, determined by total bile acid excretion, was inhibited by 77% (P less than 0.05), indicating a crucial role of CCK in regulating gallbladder motility. Except for the initial 30 minutes postprandially, MK-329 also induced a significant reduction in duodenal pH with mean values ranging from 3.5 +/- 0.2 to 4.1 +/- 0.3 compared with 4.5 +/- 0.3 to 5.0 +/- 0.4 after placebo (P less than 0.05), probably because of lowered secretion of pancreatic bicarbonate. Gastric emptying rate was significantly accelerated by MK-329 during the initial 75 minutes after the meal, but the time for 50% emptying did not differ from placebo [127.5 +/- 7.7 vs. 140.0 +/- 9.0 minutes (NS)]. No changes were observed in the motility pattern of the proximal duodenum after feeding. Whereas MK-329 only caused a slight increase of the basal plasma CCK concentrations, the postprandial levels were markedly enhanced. Peak concentrations were 10.0 +/- 1.3 vs. 4.0 +/- 0.5 pmol/L after placebo (P less than 0.001), and the integrated response exceeded the control value by 175% (P less than 0.01). The results suggest that circulating CCK is not an essential mediator of the postprandial pancreatic enzyme secretion in humans, whereas it plays a critical role in gallbladder emptying.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568584     DOI: 10.1016/0016-5085(92)91738-p

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

Review 1.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

2.  Ildr1 gene deletion protects against diet-induced obesity and hyperglycemia.

Authors:  Rashmi Chandra; Dipendra K Aryal; Jonathan D Douros; Rafiq Shahid; Supriya J Davis; Jonathan E Campbell; Olga Ilkayeya; Phillip J White; Ramona Rodriguez; Christopher B Newgard; William C Wetsel; Rodger A Liddle
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

Review 3.  Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones.

Authors:  Amosy E M'Koma; Paul E Wise; Roberta L Muldoon; David A Schwartz; Mary K Washington; Alan J Herline
Journal:  Int J Colorectal Dis       Date:  2007-06-19       Impact factor: 2.571

4.  Time-course of the pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor.

Authors:  B Ohlsson; J Axelson; B Sternby; J F Rehfeld; I Ihse
Journal:  Int J Pancreatol       Date:  1995-08

5.  Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion.

Authors:  Rashmi Chandra; Yu Wang; Rafiq A Shahid; Steven R Vigna; Neil J Freedman; Rodger A Liddle
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

6.  The effect of intermittent injections of CCK-8S and the CCK-A receptor antagonist devazepide on cell proliferation in exocrine rat pancreas.

Authors:  B Ohlsson; K Borg; J F Rehfeld; I Ihse; J Axelson
Journal:  Int J Pancreatol       Date:  1998-12

7.  Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist.

Authors:  T Akiyama; I Tachibana; Y Hirohata; H Shirohara; M Yamamoto; M Otsuki
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

8.  Oxytocin and cholecystokinin secretion in women with colectomy.

Authors:  Bodil Ohlsson; Jens F Rehfeld; Mary L Forsling
Journal:  BMC Gastroenterol       Date:  2004-10-07       Impact factor: 3.067

9.  Pathology review of proliferative lesions of the exocrine pancreas in two chronic feeding studies in rats with ammonium perfluorooctanoate.

Authors:  Jessica M Caverly Rae; Steven R Frame; Gerald L Kennedy; John L Butenhoff; Shu-Ching Chang
Journal:  Toxicol Rep       Date:  2014-05-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.